Please ensure Javascript is enabled for purposes of website accessibility

IVIg available under national blood arrangements for VITT

Home » News » IVIg available under national blood arrangements for VITT

The National Blood Authority (NBA) has been monitoring the rapidly evolving situation with regard to vaccine-induced immune thrombotic thrombocytopenia (VITT), otherwise known as thrombosis with thrombocytopenia syndrome (TTS) or vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) following COVID-19 vaccination.  

The NBA has temporarily added VITT as a condition to Version 3 of the Criteria for the Clinical Use of Immunoglobulin in Australia (Criteria) to enable supply of intravenous immunoglobulin (IVIg) under the national blood arrangements for cases of genuine need. Referencing THANZ advice dated  17 April 2021, the Criteria for VITT, as it appears in BloodSTAR, can be found at changes implemented by the NBA will ensure nationally consistent access to IVIg and remove the need to rely on access under Jurisdictional Direct Order arrangements for such cases. It will also support the continued rollout of the COVID-19 vaccine in Australia.The addition of VITT to the Criteria is temporary and the normal processes of evaluation and further criteria development will be undertaken by the relevant NBA Specialist Working Groups and its National Immunoglobulin Governance Advisory Committee.

Share public content to
Leave a Reply
    Our Sponsors

    2024 Corporate Sponsor

    THANZ receives financial assistance from the following corporate supporter
    © 2024
     Thrombosis & Haemostasis Society of Australia and New Zealand